177 related articles for article (PubMed ID: 26553684)
21. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults.
Kshirsagar N; Mur N; Thatte U; Gogtay N; Viviani S; Préziosi MP; Elie C; Findlow H; Carlone G; Borrow R; Parulekar V; Plikaytis B; Kulkarni P; Imbault N; LaForce FM
Vaccine; 2007 Sep; 25 Suppl 1():A101-7. PubMed ID: 17532101
[TBL] [Abstract][Full Text] [Related]
22. Higher Tetanus Toxoid Immunity 2 Years After PsA-TT Introduction in Mali.
Basta NE; Borrow R; Berthe A; Onwuchekwa U; Dembélé AT; Almond R; Frankland S; Patel S; Wood D; Nascimento M; Manigart O; Trotter CL; Greenwood B; Sow SO
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S578-85. PubMed ID: 26553691
[TBL] [Abstract][Full Text] [Related]
23. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
[TBL] [Abstract][Full Text] [Related]
24. Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.
Quiambao BP; Jain H; Bavdekar A; Dubey AP; Kolhe D; Bianco V; Van der Wielen M; Miller JM
Hum Vaccin Immunother; 2016 Aug; 12(8):2162-2168. PubMed ID: 27152501
[TBL] [Abstract][Full Text] [Related]
25. Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.
Borja-Tabora CF; Montalban C; Memish ZA; Boutriau D; Kolhe D; Miller JM; Van der Wielen M
BMC Infect Dis; 2015 Oct; 15():409. PubMed ID: 26437712
[TBL] [Abstract][Full Text] [Related]
26. A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years.
Vesikari T; Forstén A; Boutriau D; Bianco V; Van der Wielen M; Miller JM
Hum Vaccin Immunother; 2012 Dec; 8(12):1882-91. PubMed ID: 23032168
[TBL] [Abstract][Full Text] [Related]
27. A phase II, randomized study on an investigational DTPw-HBV/Hib-MenAC conjugate vaccine administered to infants in Northern Ghana.
Hodgson A; Forgor AA; Chandramohan D; Reed Z; Binka F; Bevilacqua C; Boutriau D; Greenwood B
PLoS One; 2008 May; 3(5):e2159. PubMed ID: 18478093
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.
Nolan T; Booy R; Marshall HS; Richmond P; Nissen M; Ziegler JB; Baine Y; Traskine M; Jastorff A; Van der Wielen M
Pediatr Infect Dis J; 2019 Jun; 38(6):643-650. PubMed ID: 31116180
[TBL] [Abstract][Full Text] [Related]
29. Five-year Antibody Persistence and Booster Response After 1 or 2 Doses of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Healthy Children.
Klein NP; Baine Y; Kolhe D; Baccarini CI; Miller JM; Van der Wielen M
Pediatr Infect Dis J; 2016 Jun; 35(6):662-72. PubMed ID: 26928521
[TBL] [Abstract][Full Text] [Related]
30. Antibody persistence following meningococcal ACWY conjugate vaccine licensed in the European Union by age group and vaccine.
Luo W; Arkwright PD; Borrow R
Expert Rev Vaccines; 2020 Aug; 19(8):745-754. PubMed ID: 32897762
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.
Rivera L; Schwarz TF; Kim KH; Kim YK; Behre U; Cha SH; Jo DS; Lee J; Lee JS; Cheuvart B; Jastorff A; Van der Wielen M
Vaccine; 2018 Jul; 36(31):4750-4758. PubMed ID: 29960800
[TBL] [Abstract][Full Text] [Related]
32. Effect of Tdap upon antibody response to meningococcal polysaccharide when administered before, with or after the quadrivalent meningococcal TT-conjugate vaccine (coadministered with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj pilgrims: A randomised controlled trial.
Tashani M; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Rashid H; Findlow H; Borrow R; Booy R
Vaccine; 2018 Jul; 36(29):4375-4382. PubMed ID: 29880243
[TBL] [Abstract][Full Text] [Related]
33. MenAfriVac as an Antitetanus Vaccine.
Borrow R; Tang Y; Yakubu A; Kulkarni PS; LaForce FM
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S570-7. PubMed ID: 26553690
[TBL] [Abstract][Full Text] [Related]
34. Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study.
Khatami A; Snape MD; Wysocki J; John TM; Westcar S; Mesaros N; Peddiraju K; Boutriau D; Yu LM; Pollard AJ
Pediatr Infect Dis J; 2012 Oct; 31(10):1069-73. PubMed ID: 22673139
[TBL] [Abstract][Full Text] [Related]
35. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT).
Østergaard L; Van der Wielen M; Bianco V; Miller JM
Int J Infect Dis; 2013 Mar; 17(3):e173-6. PubMed ID: 23246368
[TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of fractional dose intradermal injection of two quadrivalent conjugated meningococcal vaccines.
Jonker EFF; van Ravenhorst MB; Berbers GAM; Visser LG
Vaccine; 2018 Jun; 36(26):3727-3732. PubMed ID: 29778515
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.
Dbaibo G; El-Ayoubi N; Ghanem S; Hajar F; Bianco V; Miller JM; Mesaros N
Drugs Aging; 2013 May; 30(5):309-19. PubMed ID: 23494214
[TBL] [Abstract][Full Text] [Related]
38. Antibody persistence and booster response 68 months after vaccination at 2-10 years of age with one dose of MenACWY-TT conjugate vaccine.
Knuf M; Helm K; Kolhe D; Van Der Wielen M; Baine Y
Vaccine; 2018 May; 36(23):3286-3295. PubMed ID: 29724511
[TBL] [Abstract][Full Text] [Related]
39. Preclinical immunogenicity study of trivalent meningococcal AWX-OMV vaccines for the African meningitis belt.
Tunheim G; Naess LM; Acevedo R; Fjeldheim ÅK; Bolstad K; García L; Cardoso D; Aase A; Zayas C; González H; Rosenqvist E; Norheim G
Vaccine; 2014 Nov; 32(49):6631-8. PubMed ID: 25305564
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
